320 related articles for article (PubMed ID: 31590683)
21. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
22. CRISPR editing of sftb-1/SF3B1 in Caenorhabditis elegans allows the identification of synthetic interactions with cancer-related mutations and the chemical inhibition of splicing.
Serrat X; Kukhtar D; Cornes E; Esteve-Codina A; Benlloch H; Cecere G; Cerón J
PLoS Genet; 2019 Oct; 15(10):e1008464. PubMed ID: 31634348
[TBL] [Abstract][Full Text] [Related]
23. DiscoverSL: an R package for multi-omic data driven prediction of synthetic lethality in cancers.
Das S; Deng X; Camphausen K; Shankavaram U
Bioinformatics; 2019 Feb; 35(4):701-702. PubMed ID: 30059974
[TBL] [Abstract][Full Text] [Related]
24. Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs.
Jackson RA; Chen ES
Pharmacol Ther; 2016 Jun; 162():69-85. PubMed ID: 26803999
[TBL] [Abstract][Full Text] [Related]
25. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
26. Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements.
Mizuarai S; Kotani H
Hum Genet; 2010 Dec; 128(6):567-75. PubMed ID: 20976469
[TBL] [Abstract][Full Text] [Related]
27. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.
Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T
Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525
[TBL] [Abstract][Full Text] [Related]
28. SWI/SNF chromatin remodeling and human malignancies.
Masliah-Planchon J; Bièche I; Guinebretière JM; Bourdeaut F; Delattre O
Annu Rev Pathol; 2015; 10():145-71. PubMed ID: 25387058
[TBL] [Abstract][Full Text] [Related]
29. SWI/SNF complex, promising target in melanoma therapy: Snapshot view.
Mollapour Sisakht M; Amirkhani MA; Nilforoushzadeh MA
Front Med (Lausanne); 2023; 10():1096615. PubMed ID: 36844227
[TBL] [Abstract][Full Text] [Related]
30. Synthetic lethal genetic screens in Ras mutant cancers.
Yu B; Luo J
Enzymes; 2013; 34 Pt. B():201-19. PubMed ID: 25034106
[TBL] [Abstract][Full Text] [Related]
31. High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions.
Mues M; Karra L; Romero-Moya D; Wandler A; Hangauer MJ; Ksionda O; Thus Y; Lindenbergh M; Shannon K; McManus MT; Roose JP
Cell Rep; 2019 Apr; 27(2):631-647.e5. PubMed ID: 30970263
[TBL] [Abstract][Full Text] [Related]
32. Synthetically Lethal Interactions of ATM, ATR, and DNA-PKcs.
Kantidze OL; Velichko AK; Luzhin AV; Petrova NV; Razin SV
Trends Cancer; 2018 Nov; 4(11):755-768. PubMed ID: 30352678
[TBL] [Abstract][Full Text] [Related]
33. Synthetic lethal vulnerabilities of cancer.
Fece de la Cruz F; Gapp BV; Nijman SM
Annu Rev Pharmacol Toxicol; 2015; 55():513-31. PubMed ID: 25340932
[TBL] [Abstract][Full Text] [Related]
34. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
Elife; 2017 Oct; 6():. PubMed ID: 28967863
[TBL] [Abstract][Full Text] [Related]
35. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
[TBL] [Abstract][Full Text] [Related]
36. BRCA1 deficiency and synthetic lethality in leukemias; not only gene mutation matters.
Piwocka K; Podszywałow-Bartnicka P; Skorski T
Postepy Biochem; 2018 Oct; 64(2):141-147. PubMed ID: 30656896
[TBL] [Abstract][Full Text] [Related]
37. Identification of synthetic lethality based on a functional network by using machine learning algorithms.
Li J; Lu L; Zhang YH; Liu M; Chen L; Huang T; Cai YD
J Cell Biochem; 2019 Jan; 120(1):405-416. PubMed ID: 30125975
[TBL] [Abstract][Full Text] [Related]
38. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
[TBL] [Abstract][Full Text] [Related]
39. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
Czyż M; Toma M; Gajos-Michniewicz A; Majchrzak K; Hoser G; Szemraj J; Nieborowska-Skorska M; Cheng P; Gritsyuk D; Levesque M; Dummer R; Sliwinski T; Skorski T
Oncotarget; 2016 Nov; 7(46):75551-75560. PubMed ID: 27705909
[TBL] [Abstract][Full Text] [Related]
40. Targeting "undruggable" c-Myc protein by synthetic lethality.
Wang C; Fang H; Zhang J; Gu Y
Front Med; 2021 Aug; 15(4):541-550. PubMed ID: 33660217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
